Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
STATE NET® THOUGHT LEADERSHIP SERIES How Historic Adoption Rates Hold the Key to Forecasting Future Regulatory Action Just as state legislatures vary in their bill passage rates, some state agencies...
Judge Strikes Down Part of MD Digital Ad Tax Law A federal judge struck down a provision of Maryland’s first-in-the-nation digital advertising tax law that prohibited online companies from notifying...
NLRB Sues California to Block Labor Board Law The National Labor Relations Board has filed a lawsuit to block a new California law ( AB 288 ) empowering the state’s Public Employee Relations Board...
TX AG Sues Johnson & Johnson over Claimed Tylenol-Autism Link Texas Attorney General Ken Paxton (R) filed a lawsuit against Johnson & Johnson this week claiming the company hid the risks of Tylenol...
Over the past 47 years, seven states have enacted their own, state-level versions of the federal Community Reinvestment Act to ensure financial institutions within their jurisdictions are meeting the banking...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
On Oct. 3 Colorado’s Prescription Drug Affordability Review Board set an upper payment limit, or UPL, for Enbrel, a prescription drug used to treat rheumatoid arthritis and other autoimmune diseases. The cap—limiting what insurers and patients pay for the medication to no more than about $31,000 per year, nearly half the $53,049 average amount insurance plans paid for the drug in 2023—is the first such limit to be imposed in the nation. (COLORADO SUN)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.